FDA Brief

Warning letters Drugs

FDA warning letter to

PekCura Labs

High riskIssued Mar 31Posted Apr 7Center for Drug Evaluation and Research (CDER)

FDA warned PekCura Labs that its GLP-1-S, GLP-2-T, GLP-3-R, and bacteriostatic water products are unapproved new drugs sold online.

What happened

FDA reviewed PekCura Labs' website in January 2026 and found it offered GLP-1-S, GLP-2-T, GLP-3-R, a Cag/Tirz blend, and Bacteriostatic Water for sale in the United States. The site's labeling included claims about weight loss, blood sugar, cardiovascular outcomes, and metabolic effects, which FDA said showed the products were intended for human use as drugs despite 'Research use only' and 'Not for Human consumption' statements; FDA also said no approved drug applications were in effect.

What FDA found

  1. The products are unapproved new drugs because no FDA-approved application is in effect for them, and selling them across state lines violates the law.

    FD&C Act §§301(d), 505(a); 21 U.S.C. §§331(d), 355(a)
  2. Website labeling shows the products are intended to treat or affect the body, such as for weight loss, diabetes, and cardiovascular outcomes, so they are drugs despite research-use disclaimers.

    FD&C Act §201(g)(1); 21 CFR 201.128
  3. The products are new drugs because they are not generally recognized as safe and effective for the uses described in their labeling.

    FD&C Act §201(p); 21 U.S.C. §321(p)
  4. Bacteriostatic Water is sold with injectable peptides that need reconstitution, which FDA says shows it is intended for injection and is therefore a drug.

    FD&C Act §201(g)(1); 21 U.S.C. §321(g)(1)

What FDA wants

FDA asks PekCura Labs to notify it in writing within 15 working days of the specific steps taken to correct the violations, including documentation, and to send the response to FDAAdvisory@fda.hhs.gov with the firm name and identifier 721709. If correction cannot be completed in that time, the company must state the reason and when it will be completed.

Who should pay attention

  • online sellers of peptide or GLP-1-like products
  • companies marketing injectables as research-use-only
  • suppliers and buyers of bacteriostatic water

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk